Strata Critical Medical, Inc. (SRTA)
NASDAQ:SRTA
Want to see SRTA full AI Analyst Report?
SRTA Stock Chart & Stats
$4.57
--
Market closed
$4.57
--
Day’s Range― - ―
52-Week Range$3.49 - $6.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)980.90K
Market Cap
$545.98M
Enterprise Value$491.73M
Total Cash (Recent Filing)$58.79M
Total Debt (Recent Filing)$4.47M
Price to Earnings (P/E)10.3
Beta2.06
Next Earnings
Aug 11, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding86,526,570
10 Day Avg. Volume1,050,472
30 Day Avg. Volume980,896
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit9.42
Enterprise Value/Ebitda-87.98
Forecast
1Y Price Target
$9.17Price Target Upside100.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$271.35M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and substantial equity provide durable financial flexibility: supports aircraft purchases, hub expansion and M&A, reduces refinancing and liquidity risk, and cushions operating volatility. This downside protection is a multi-quarter tailwind for execution and strategic optionality.
High-Margin Clinical Build-outRapid expansion of Clinical services with higher gross margins diversifies revenue away from lower-margin Logistics. Durable cross-sell and new customer onboarding indicate structural margin improvement potential, supporting long-term profitability even if Logistics margins fluctuate.
Strong Top-Line GrowthSustained high revenue growth signals rising market adoption and scale benefits for operations. As revenue scales, fixed-cost absorption can lift adjusted EBITDA margins and create a pathway for improved cash generation if growth is maintained and mix shifts toward higher-margin Clinical services.
Bears Say
Persistent Cash BurnMaterial and persistent negative operating and free cash flow increases reliance on balance sheet liquidity and potential external financing. Over several quarters this undermines earnings quality, constrains reinvestment flexibility, and raises risk if growth or margin improvement stalls.
Core Operating LossesProfitability driven by non-operating items means core business economics remain unproven. If one-time gains or accounting items reverse, reported net income could deteriorate; sustained value requires converting operating losses into recurring operating profits.
Margin Volatility From Mix & Donor UncertaintyDependence on customer mix (OPOs vs transplant centers), donor-volume variability and weather-related disruptions produce structural margin unpredictability. This weakens forecasting, complicates capacity planning and increases the need for liquidity buffers to manage uneven cash flows.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical, Inc.’s price range in the past 12 months?
Strata Critical Medical, Inc. lowest stock price was $3.48 and its highest was $6.50 in the past 12 months.
What is Strata Critical Medical, Inc.’s market cap?
Strata Critical Medical, Inc.’s market cap is $545.98M.
When is Strata Critical Medical, Inc.’s upcoming earnings report date?
Strata Critical Medical, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 69 days.
How were Strata Critical Medical, Inc.’s earnings last quarter?
Strata Critical Medical, Inc. released its earnings results on May 06, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.068.
Is Strata Critical Medical, Inc. overvalued?
According to Wall Street analysts Strata Critical Medical, Inc.’s price is currently Undervalued.
Does Strata Critical Medical, Inc. pay dividends?
Strata Critical Medical, Inc. does not currently pay dividends.
What is Strata Critical Medical, Inc.’s EPS estimate?
Strata Critical Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Strata Critical Medical, Inc. have?
Strata Critical Medical, Inc. has 86,526,570 shares outstanding.
What happened to Strata Critical Medical, Inc.’s price movement after its last earnings report?
Strata Critical Medical, Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went up 10.581%.
Which hedge fund is a major shareholder of Strata Critical Medical, Inc.?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.17 (100.58% Upside)
$9.17 (100.58% Upside)
Blogger Sentiment
Bullish
SRTA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.35%
12-Months-Change
Fundamentals
Return on Equity
18.97%
Trailing 12-Months
Asset Growth
30.76%
Trailing 12-Months
Company Description
Strata Critical Medical, Inc.
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
SRTA Company Deck
SRTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive tone driven by very strong year-over-year revenue (+87.4%), doubled gross profit, rapid build-out and commercial traction in the Clinical business, healthy cash on hand and an active M&A pipeline. Offsetting these positives were sequential softness in Logistics revenue and margins (customer mix and weather-related disruptions), a sequential decline in adjusted EBITDA margin, some one-time cash timing effects, and ongoing uncertainty in donor volumes. Management reiterated full-year guidance and highlighted balance sheet capacity, suggesting confidence in execution despite near-term noise.View all SRTA earnings summariesSRTA Stock 12 Month Forecast
Average Price Target
$9.17
▲(100.58% Upside)
Technical Analysis
Ownership Overview
14.99% Insiders
12.08% Mutual Funds
38.49% Other Institutional Investors
18.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---